Due to concerns about the side effects of the drug, some countries have restricted the use of the drug in the elderly.
London- The British drug regulator said it had identified 30 cases of thrombosis and abnormal blood clotting problems related to the coronavirus vaccine developed by AstraZeneca and Oxford University, but reiterated that its benefits “continue to outweigh any risks.”
Drug and health product regulators point out that the risk associated with this type of blood clot is “very small”, so people should continue to be vaccinated whenever there is a chance.
The regulator explained on Friday evening that the cases were related to the period until March 24, during which a total of 18.1 million doses of vaccine were vaccinated. He added that it has not received similar reports about Pfizer-BioNTech’s development.
Concerns about the side effects of AstraZeneca’s drugs have led to restrictions on its use in the elderly in many countries including Canada, France, Germany and the Netherlands.
The World Health Organization has asked countries to continue to use the vaccine.